Simultaneous occurrence of Hodgkin's disease, nodal Langerhans' cell histiocytosis and multiple myeloma IgA(κ)

Andres, Cesar; Toscano, Ricardo; Lahuerta, Juan-José; Martínez-González, M Á

doi:10.1007/s004280050338

Cited by 21 publications

(12 citation statements)

References 20 publications

(25 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Those HRS cells that continue to express SDC1 are perhaps more aggressive than their SDC1 negative counterparts, thus contributing to the aggressive nature of poor outcome cHL, and producing the sort of unfavorable prognosis that is typical of primary refractory and early relapsing cHL patients. Of additional interest is the coexistence of HRS cells with aggressive multiple myeloma [65], or their appearance after treatment of multiple myeloma [66]. …”

Section: Discussionmentioning

confidence: 99%

Fibroblast growth factor-2 (FGF2) and syndecan-1 (SDC1) are potential biomarkers for putative circulating CD15+/CD30+ cells in poor outcome Hodgkin lymphoma patients

et al. 2013

View full text Add to dashboard Cite

BackgroundHigh risk, unfavorable classical Hodgkin lymphoma (cHL) includes those patients with primary refractory or early relapse, and progressive disease. To improve the availability of biomarkers for this group of patients, we investigated both tumor biopsies and peripheral blood leukocytes (PBL) of untreated (chemo-naïve, CN) Nodular Sclerosis Classic Hodgkin Lymphoma (NS-cHL) patients for consistent biomarkers that can predict the outcome prior to frontline treatment.Methods and materialsBioinformatics data mining was used to generate 151 candidate biomarkers, which were screened against a library of 10 HL cell lines. Expression of FGF2 and SDC1 by CD30+ cells from HL patient samples representing good and poor outcomes were analyzed by qRT-PCR, immunohistochemical (IHC), and immunofluorescence analyses.ResultsTo identify predictive HL-specific biomarkers, potential marker genes selected using bioinformatics approaches were screened against HL cell lines and HL patient samples. Fibroblast Growth Factor-2 (FGF2) and Syndecan-1 (SDC1) were overexpressed in all HL cell lines, and the overexpression was HL-specific when compared to 116 non-Hodgkin lymphoma tissues. In the analysis of stratified NS-cHL patient samples, expression of FGF2 and SDC1 were 245 fold and 91 fold higher, respectively, in the poor outcome (PO) group than in the good outcome (GO) group. The PO group exhibited higher expression of the HL marker CD30, the macrophage marker CD68, and metastatic markers TGFβ1 and MMP9 compared to the GO group. This expression signature was confirmed by qualitative immunohistochemical and immunofluorescent data. A Kaplan-Meier analysis indicated that samples in which the CD30+ cells carried an FGF2+/SDC1+ immunophenotype showed shortened survival. Analysis of chemo-naive HL blood samples suggested that in the PO group a subset of CD30+ HL cells had entered the circulation. These cells significantly overexpressed FGF2 and SDC1 compared to the GO group. The PO group showed significant down-regulation of markers for monocytes, T-cells, and B-cells. These expression signatures were eliminated in heavily pretreated patients.ConclusionThe results suggest that small subsets of circulating CD30+/CD15+ cells expressing FGF2 and SDC1 represent biomarkers that identify NS-cHL patients who will experience a poor outcome (primary refractory and early relapsing).

show abstract

Section: Discussionmentioning

confidence: 99%

Fibroblast growth factor-2 (FGF2) and syndecan-1 (SDC1) are potential biomarkers for putative circulating CD15+/CD30+ cells in poor outcome Hodgkin lymphoma patients

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Analyses of lymphomas with an excess of LC are few in as [8][9][10][11][12] with an occasional series of four or six patients and review of the literature [3,4]. Our series, the largest to be reported, studies many clinical and pathological issues and provides analysis of the significance of this association.…”

Section: Discussionmentioning

confidence: 85%

High content of Langerhans cells in malignant lymphoma—incidence and significance

et al. 2010

View full text Add to dashboard Cite

We describe 25 patients, 14 with classical Hodgkin lymphoma and 11 with non-Hodgkin lymphoma, in all of whom an excess of Langerhans cells was evident. Except for the first three cases, in which the excess of Langerhans cells was identified on routine slides, the remaining cases were disclosed by actively investigating lymphomas with excess of CD68+ histiocytes and performing CD1a and S-100 protein immunostains. Although no clonality study was performed on the Langerhans cells, we endorse the view which states that in the above association, the Langerhans cells are polyclonal. Fourteen cases of Hodgkin lymphoma with a large number of Langerhans cells were identified in a cohort of 231 classical Hodgkin lymphomas. We compared the features of classical Hodgkin lymphoma with abundant Langerhans cells with those without Langerhans cells. Our analysis reveals that Hodgkin lymphoma with Langerhans cell excess shows greater LMP1/EBV expression (P = .007) and lower p53 expression (P = .042) in the Hodgkin-Reed-Sternberg cells but is not associated with a poorer outcome.

show abstract

“…One case of developing HD after LCH has also been reported [6]. Ibarrola de Andres C. et al reported simultaneous occurrence of Hodgkin's disease, Langerhans cell histiocytosis and multiple myeloma in a 35-year-old man [7] while Karadeniz G. et al reported the simultaneous development of HD and LCH in a 6-year-old boy [8] and Kjeldsberg C. R. et al described the combination of eosinophilic granuloma and malignant lymphoma in the same lymph node [5]. …”

Section: Discussionmentioning

confidence: 99%

Synchronously diagnosed eosinophilic granuloma and Hodgkin's disease in a 12-year-old boy: a case report

et al. 2009

View full text Add to dashboard Cite

IntroductionSynchronous composite tumors are uncommon. Simultaneous, rather than metachronous or consecutive, occurrences of eosinophilic granuloma and Hodgkin's lymphoma in children are very rare. This is the first report of this kind in the medical literature.Case presentationWe report the case of a 12-year-old Iranian boy with eosinophilic granuloma localized in his leg around the knee and Hodgkin's lymphoma in a cervical lymph node. The two tumours occurred synchronously before the patient had received any treatment.ConclusionSeveral cases of an association between eosinophilic granuloma and lymphoproliferative disorder have been reported. Some of these cases involve Hodgkin's lymphoma and Langerhans cell histiocytosis occurring in the same patient. Genetic or environmental etiologies have been postulated for eosinophilic granulomas which occur following Hodgkin's lymphomas, but have as yet not been proven. To our knowledge, synchronous occurrence of these two malignant processes in a patient who has not received any prior treatment is rare in children.

show abstract

Simultaneous occurrence of Hodgkin's disease, nodal Langerhans' cell histiocytosis and multiple myeloma IgA(κ)

Cited by 21 publications

References 20 publications

Fibroblast growth factor-2 (FGF2) and syndecan-1 (SDC1) are potential biomarkers for putative circulating CD15+/CD30+ cells in poor outcome Hodgkin lymphoma patients

Fibroblast growth factor-2 (FGF2) and syndecan-1 (SDC1) are potential biomarkers for putative circulating CD15+/CD30+ cells in poor outcome Hodgkin lymphoma patients

High content of Langerhans cells in malignant lymphoma—incidence and significance

Synchronously diagnosed eosinophilic granuloma and Hodgkin's disease in a 12-year-old boy: a case report

Contact Info

Product

Resources

About